Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 7/20 | 0.40 |
| ▸ | HTR1A | P08908 | 6/20 | 0.40 |
| ▸ | DRD1 | P21728 | 6/20 | 0.40 |
| ▸ | DRD4 | P21917 | 6/20 | 0.40 |
| ▸ | DRD5 | P21918 | 6/20 | 0.40 |
| ▸ | DRD2 | P14416 | 5/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5757025 | 0.90 | OPRM1 (0.45) | DRD3OPRM1OPRD1OPRK1KCNH2 | |
| SCHEMBL5753298 | 0.89 | OPRM1 (0.40) | DRD3HTR1ADRD1DRD4DRD5 | |
| SCHEMBL5756851 | 0.86 | TSHR (0.39) | DRD3HTR1ADRD1DRD4DRD5 | |
| SCHEMBL5754428 | 0.84 | OPRM1 (0.46) | DRD3HTR1ADRD1DRD4DRD5 | |
| SCHEMBL5755228 | 0.84 | OPRM1 (0.40) | DRD3OPRM1OPRD1OPRK1KCNH2 | |
| SCHEMBL5756107 | 0.82 | GRM2 (0.41) | DRD3HTR1ADRD1DRD4DRD5 | |
| SCHEMBL5754109 | 0.81 | ALDH1A1 (0.40) | DRD3OPRM1OPRD1OPRK1KCNH2 | |
| SCHEMBL5756317 | 0.80 | OPRM1 (0.63) | OPRM1OPRD1OPRK1KCNH2 | |
| SCHEMBL5756319 | 0.80 | DRD3 (0.39) | DRD3HTR1ADRD1DRD4DRD5 | |
| SCHEMBL5401222 | 0.79 | DRD3 (0.43) | DRD3HTR1ADRD1DRD4DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1140828-B1 | 3-AZABICYCLO¬3.1.0|HEXANE DERIVATIVES AS OPIATE RECEPTORS LIGANDS | PFIZER LTD (GB) | 2006-08-09 | — | — | EP | disclosed |
| US-7049444-B2 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | PFIZER INC. (US) | 2006-05-23 | — | — | US | disclosed |
| US-20030013875-A1 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | PFIZER, INC. (US) | 2003-01-16 | — | — | US | disclosed |
| US-20020072616-A1 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | PFIZER INC. | 2002-06-13 | — | — | US | disclosed |
| US-6313312-B1 | OPIATE RECEPTOR BINDERS; ALLERGIC DERMATITIS, PRURITUS; IRRITABLE BOWEL SYNDROME, GASTROINTESTINAL AND SKIN DISORDERS; VETERINARY MEDICINE; ANTI-ITCHING | PFIZER INC | 2001-11-06 | — | — | US | disclosed |
| EP-1140828-A1 | 3-AZABICYCLO[3.1.0]HEXANE DERIVATIVES AS OPIATE RECEPTORS LIGANDS | Pfizer Limited (GB) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039089-A1 | 3-AZABICYCLO[3.1.0.] HEXANE DERIVATIVES AS OPIATE RECEPTORS LIGANDS | PFIZER LIMITED (GB) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072616-A1 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | OPRM1, OPRK1, OPRD1 | DRD3 245/4885HTR1A 104/4885DRD1 369/4885 |
| US-20030013875-A1 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | OPRM1, OPRK1, OPRD1 | DRD3 245/4885HTR1A 104/4885DRD1 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.